logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2018—Modestly improved PFS with taselisib added to fulvestrant in PIK3CA-mutant breast cancer

PFS improved by 2 months, but high toxicity is a concern.